| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Chemistry, Vol 38, 2078-2081, Copyright © 1992 by American Association for Clinical Chemistry
J Beilby, J Olynyk, S Ching, A Prins, N Swanson, W Reed, H Harley and P Garcia-Webb
Department of Clinical Biochemistry, Queen Elizabeth II Medical Centre, Nedlands, Western Australia.
We surveyed 140 clinical chemistry laboratories in Australia to establish which laboratory methods they used to determine serum iron status: 125 measured serum iron (Fe), 85 measured transferrin (TRF), 47 measured total iron-binding capacity (TIBC), and 14 measured both TRF and TIBC. Of the 55 laboratories routinely reporting TRF saturation (TS), 16 calculated TS directly as (Fe/TIBC) x 100, and 9 used [Fe/(TRF x 2)] x 100. Thirty laboratories measured TRF and converted it to an equivalent TIBC concentration; the derived TIBC was then used to calculate TS. We measured iron, TIBC, and TRF concentrations in 94 control subjects, 59 patients with alcoholic liver disease (ALD), and 20 with proven genetic hemochromatosis (GH). TS was compared with a transferrin index (TI = Fe/TRF) to determine whether both methods were sensitive for GH screening and which method gave the fewest false- positive results with discrimination limits of > 55% and > 1.0, respectively. All GH patients were detected by both TS and TI at these limits. One control subject had a TI > 1.0, whereas three control subjects had a TS > 55%. Nine patients with ALD had a TI > 1.0 and 11 ALD patients had a TS > 55%. Some iron-overload patients had lower than expected TS values compared with TI, possibly because of ferritin interference in the TIBC assay. Also, the precision of the TRF assay was better than that of the TIBC assay: CVs of 1.85-3.68% vs 6.17%. We therefore recommend that calculated TI replace TS in screening for iron overload.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L. von Bonsdorff, E. Lindeberg, L. Sahlstedt, J. Lehto, and J. Parkkinen Bleomycin-detectable Iron Assay for Non-Transferrin-bound Iron in Hematologic Malignancies Clin. Chem., February 1, 2002; 48(2): 307 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Siek, J. Lawlor, D. Pelczar, M. Sane, and J. Musto Direct Serum Total Iron-binding Capacity Assay Suitable for Automated Analyzers Clin. Chem., January 1, 2002; 48(1): 161 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Olynyk, D. J. Cullen, S. Aquilia, E. Rossi, L. Summerville, and L. W. Powell A Population-Based Study of the Clinical Expression of the Hemochromatosis Gene N. Engl. J. Med., September 2, 1999; 341(10): 718 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gambino, E. Desvarieux, M. Orth, H. Matan, T. Ackattupathil, E. Lijoi, C. Wimmer, J. Bower, and E. Gunter The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum Clin. Chem., December 1, 1997; 43(12): 2408 - 2412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Punnonen, K. Irjala, and A. Rajamaki Serum Transferrin Receptor and Its Ratio to Serum Ferritin in the Diagnosis of Iron Deficiency Blood, February 1, 1997; 89(3): 1052 - 1057. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
